XML 260 R214.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segment information - Summary of Net Sales by Segment and Geographical Area (Details) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2023 EUR (€) segment | Dec. 31, 2022 EUR (€) segment | Dec. 31, 2021 EUR (€)
Disclosure of geographical areas [line items] |  |  |
Net sales | € 43,070 | € 42,997 | € 37,761
Number of operating segments | segment | 2 | 3 |
Biopharma |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | € 37,890 | € 37,812 | 33,293
Biopharma | Specialty Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 18,040 | 16,457 | 12,752
Biopharma | DUPIXENT |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 10,715 | 8,293 | 5,249
Biopharma | AUBAGIO |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 955 | 2,031 | 1,955
Biopharma | CEREZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 687 | 707 | 683
Biopharma | FABRAZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 991 | 938 | 844
Biopharma | MYOZYME/ LUMIZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 783 | 958 | 1,003
Biopharma | JEVTANA |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 320 | 391 | 455
Biopharma | ALPROLIX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 540 | 504 | 414
Biopharma | ELOCTATE |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 471 | 580 | 563
Biopharma | General Medicines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 12,376 | 14,127 | 14,218
Biopharma | Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 6,270 | 6,389 | 5,768
Biopharma | LOVENOX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,125 | 1,310 | 1,486
Biopharma | TOUJEO |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,123 | 1,117 | 969
Biopharma | PLAVIX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 948 | 983 | 929
Biopharma | Non-Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 5,524 | 7,118 | 7,642
Biopharma | LANTUS |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,420 | 2,259 | 2,494
Biopharma | Other non-core assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 3,687 | 4,381 | 4,729
Biopharma | Industrial sales |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 582 | 620 | 808
Biopharma | Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 7,474 | 7,228 | 6,323
Biopharma | Polio/Pertussis/ Hib Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,165 | 2,285 | 2,159
Biopharma | Influenza Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,669 | 2,977 | 2,628
Consumer Healthcare |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 5,180 | 5,185 | 4,468
Consumer Healthcare | Allergy |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 769 | 770 | 612
Consumer Healthcare | Pain Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,106 | 1,140 | 1,093
Consumer Healthcare | Digestive Wellness |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,502 | 1,449 | 1,131
Europe |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 10,392 | 9,999 | 9,759
Europe | Biopharma |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 8,835 | 8,498 | 8,426
Europe | Biopharma | Specialty Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 3,206 | 3,016 | 2,764
Europe | Biopharma | DUPIXENT |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,224 | 940 | 649
Europe | Biopharma | AUBAGIO |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 437 | 511 | 512
Europe | Biopharma | CEREZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 229 | 239 | 244
Europe | Biopharma | FABRAZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 241 | 228 | 223
Europe | Biopharma | MYOZYME/ LUMIZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 341 | 408 | 410
Europe | Biopharma | JEVTANA |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 12 | 33 | 112
Europe | Biopharma | ALPROLIX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 0 | 0 | 0
Europe | Biopharma | ELOCTATE |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 0 | 0 | 0
Europe | Biopharma | General Medicines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 3,932 | 4,141 | 4,437
Europe | Biopharma | Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,988 | 1,917 | 1,868
Europe | Biopharma | LOVENOX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 622 | 658 | 703
Europe | Biopharma | TOUJEO |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 441 | 421 | 394
Europe | Biopharma | PLAVIX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 96 | 101 | 115
Europe | Biopharma | Non-Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,396 | 1,637 | 1,846
Europe | Biopharma | LANTUS |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 357 | 426 | 474
Europe | Biopharma | Other non-core assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 961 | 1,129 | 1,285
Europe | Biopharma | Industrial sales |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 548 | 587 | 723
Europe | Biopharma | Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,697 | 1,341 | 1,225
Europe | Biopharma | Polio/Pertussis/ Hib Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 297 | 325 | 306
Europe | Biopharma | Influenza Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 694 | 681 | 729
Europe | Consumer Healthcare |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,557 | 1,501 | 1,333
Europe | Consumer Healthcare | Allergy |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 70 | 55 | 49
Europe | Consumer Healthcare | Pain Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 502 | 555 | 515
Europe | Consumer Healthcare | Digestive Wellness |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 520 | 432 | 389
United States |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 18,512 | 18,275 | 14,385
United States | Biopharma |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 17,265 | 16,985 | 13,246
United States | Biopharma | Specialty Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 11,917 | 10,848 | 7,847
United States | Biopharma | DUPIXENT |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 8,145 | 6,346 | 3,971
United States | Biopharma | AUBAGIO |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 460 | 1,420 | 1,312
United States | Biopharma | CEREZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 189 | 194 | 173
United States | Biopharma | FABRAZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 503 | 471 | 395
United States | Biopharma | MYOZYME/ LUMIZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 254 | 318 | 373
United States | Biopharma | JEVTANA |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 230 | 275 | 253
United States | Biopharma | ALPROLIX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 440 | 406 | 332
United States | Biopharma | ELOCTATE |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 341 | 450 | 429
United States | Biopharma | General Medicines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,084 | 2,846 | 2,637
United States | Biopharma | Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,485 | 1,653 | 1,315
United States | Biopharma | LOVENOX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 7 | 17 | 29
United States | Biopharma | TOUJEO |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 213 | 283 | 259
United States | Biopharma | PLAVIX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 8 | 9 | 9
United States | Biopharma | Non-Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 592 | 1,176 | 1,281
United States | Biopharma | LANTUS |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 281 | 757 | 861
United States | Biopharma | Other non-core assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 302 | 412 | 410
United States | Biopharma | Industrial sales |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 7 | 17 | 41
United States | Biopharma | Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 3,264 | 3,291 | 2,762
United States | Biopharma | Polio/Pertussis/ Hib Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 398 | 456 | 470
United States | Biopharma | Influenza Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,406 | 1,737 | 1,366
United States | Consumer Healthcare |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,247 | 1,290 | 1,139
United States | Consumer Healthcare | Allergy |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 412 | 439 | 371
United States | Consumer Healthcare | Pain Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 180 | 212 | 196
United States | Consumer Healthcare | Digestive Wellness |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 138 | 144 | 124
Other countries |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 14,166 | 14,723 | 13,617
Other countries | Biopharma |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 11,790 | 12,329 | 11,621
Other countries | Biopharma | Specialty Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,917 | 2,593 | 2,141
Other countries | Biopharma | DUPIXENT |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,346 | 1,007 | 629
Other countries | Biopharma | AUBAGIO |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 58 | 100 | 131
Other countries | Biopharma | CEREZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 269 | 274 | 266
Other countries | Biopharma | FABRAZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 247 | 239 | 226
Other countries | Biopharma | MYOZYME/ LUMIZYME |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 188 | 232 | 220
Other countries | Biopharma | JEVTANA |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 78 | 83 | 90
Other countries | Biopharma | ALPROLIX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 100 | 98 | 82
Other countries | Biopharma | ELOCTATE |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 130 | 130 | 134
Other countries | Biopharma | General Medicines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 6,360 | 7,140 | 7,144
Other countries | Biopharma | Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,797 | 2,819 | 2,585
Other countries | Biopharma | LOVENOX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 496 | 635 | 754
Other countries | Biopharma | TOUJEO |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 469 | 413 | 316
Other countries | Biopharma | PLAVIX |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 844 | 873 | 805
Other countries | Biopharma | Non-Core Assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 3,536 | 4,305 | 4,515
Other countries | Biopharma | LANTUS |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 782 | 1,076 | 1,159
Other countries | Biopharma | Other non-core assets |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,424 | 2,840 | 3,034
Other countries | Biopharma | Industrial sales |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 27 | 16 | 44
Other countries | Biopharma | Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,513 | 2,596 | 2,336
Other countries | Biopharma | Polio/Pertussis/ Hib Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 1,470 | 1,504 | 1,383
Other countries | Biopharma | Influenza Vaccines |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 569 | 559 | 533
Other countries | Consumer Healthcare |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 2,376 | 2,394 | 1,996
Other countries | Consumer Healthcare | Allergy |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 287 | 276 | 192
Other countries | Consumer Healthcare | Pain Care |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | 424 | 424 | 382
Other countries | Consumer Healthcare | Digestive Wellness |  |  |
Disclosure of geographical areas [line items] |  |  |
Net sales | € 844 | € 822 | € 618

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfGeographicalAreasLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of operating segments. + References No definition available. + Details
Name: | sny_NumberOfOperatingSegments1
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_SpecialtyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_DupixentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AubagioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_MyozymeOrLumizymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_JevtanaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AlprolixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_EloctateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_GeneralMedecinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_CoreAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_ToujeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PlavixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_NonCoreAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LantusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_OtherNonCoreAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_VaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AllergyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PainCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_DigestiveWellnessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |